LLY

Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC

Retrieved on: 
Tuesday, July 11, 2023
Webcast, Eli Lilly and Company, LLY, Conference, NYSE, Donanemab, Pharmaceutical industry, Broadcasting, Alzheimer's disease

INDIANAPOLIS, July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference.

Key Points: 
  • INDIANAPOLIS, July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference.
  • The webcast will begin at 1:30 p.m. Eastern time, and remarks will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer's disease.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.

DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

Retrieved on: 
Tuesday, July 11, 2023
Class Action Lawsuit, Professional Services, Legal, Eli Lilly and Company, DICE, LLY, Therapy, KSF, NYSE, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY).
  • Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

Retrieved on: 
Monday, July 10, 2023
ICIS, Immunogenic cell death, Senior, Cancer, ICD, Research, Lung cancer, Immunotherapy, Liver cancer, Sintilimab, LLY, HKEX, Patient, MSLN, Esophageal cancer, ADC, Eli Lilly and Company, Spacecraft, PD-1, Stomach, Tumor microenvironment, NRDL, NYSE, B cell, Safety, Pharmaceutical industry, Vaccine, Pharmaceutical innovations

YANTAI, China, July 9, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics ("Innovent")  (HKEX: 01801) . This collaboration will focus on conducting clinical trials exploring combination therapies of the novel antibody-drug conjugates (ADCs), RC88 (targeting MSLN) and RC108 (targeting c-MET), along with the PD-1 inhibitor sintilimab injection (TYVYT®).

Key Points: 
  • According to the agreement, Innovent will supply clinical drug supplies of sintilimab during the clinical trial collaboration, while RemeGen will conduct Phase I/IIa clinical studies in China.
  • The trials will assess the safety, tolerability, and preliminary efficacy of RC88 or RC108 combined with sintilimab in Chinese cancer patients.
  • RemeGen's independently developed ADC, RC88, targets mesothelin (MSLN) and was approved for Phase I clinical trials in China in November 2018.
  • Similarly, RC108, another ADC independently developed by RemeGen targeting c-MET, was approved for Phase I clinical trials in November 2020.

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX

Retrieved on: 
Monday, July 3, 2023
Class Action Lawsuit, Professional Services, Legal, Eli Lilly and Company, LLY, NYSE, KSF, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

Retrieved on: 
Monday, June 26, 2023
Weight, Yale School of Medicine, Insulin, Obesity, Diabetes, Doctor of Philosophy, Metabolism, Triglyceride, The New England Journal of Medicine, Yale Center for Environmental Law & Policy, Yale school, OSA, Associate, NEJM, OA, LLY, Lilly, American Diabetes Association, Overweight, Endocrinology, Biology, GIP, Eli Lilly and Company, Obstructive sleep apnea, NYSE, Safety, Conditional sentence, Glycated hemoglobin, Pharmaceutical industry, Medicine, MD

INDIANAPOLIS, June 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweighti without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg)ii. In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. The results were presented in a symposium at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in The New England Journal of Medicine (NEJM).

Key Points: 
  • In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb.
  • The results were presented in a symposium at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in The New England Journal of Medicine (NEJM).
  • Longer duration phase 3 trials will enable comprehensive evaluation of efficacy and tolerability of this potential pharmacotherapeutic for the treatment of obesity."
  • "These phase 2 data have given us confidence to further explore the potential of retatrutide in phase 3 trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively."

Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight

Retrieved on: 
Saturday, June 24, 2023
Weight, The New England Journal of Medicine, Obesity, Food, Waist, Doctor of Philosophy, Type 2 diabetes, NYSE, LLY, Lilly, Comorbidity, American Diabetes Association, Overweight, Conditional sentence, Eli Lilly and Company, Human, Medicine, Pharmaceutical industry, Copper, MD, Lancet

INDIANAPOLIS, June 23, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or overweighti. The results were shared during an oral presentation at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in the New England Journal of Medicine. Orforglipron met both primary and secondary endpoints for the efficacy estimandii and demonstrated clinically significant weight reductions in adults with obesity or overweight, with at least one weight-related comorbidity (not including type 2 diabetes).

Key Points: 
  • The results were shared during an oral presentation at the American Diabetes Association's® 83rd Scientific Sessions and were simultaneously published in the New England Journal of Medicine .
  • For those taking orforglipron, body weight continued to decrease at 36 weeks where all doses achieved body weight reductions ranging from 9.4% (21.6 lb.
  • Orforglipron (3 mg, 12 mg, 24 mg, 36 mg or 45 mg) also demonstrated weight reductions up to 10.1 kg (or 22.3 lb.)
  • We look forward to those results and the continued development of our pipeline assets that explore novel treatments for type 2 diabetes and obesity."

Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU

Retrieved on: 
Friday, June 23, 2023
Health, Pharmaceutical, University, Heart failure, Chronic kidney disease, European Medicines Agency, Committee on Herbal Medicinal Products, Type 2 diabetes, Multimedia, SGLT2, Empagliflozin, Committee, EMA, Boehringer Ingelheim, Scientist, LLY, Lilly, Kidney, Committee for Medicinal Products for Human Use, Eli Lilly and Company, EMPA, CKD, Death, NYSE, Kidney disease, CHMP, Pharmaceutical industry, EU, F.A.C.E

“The approval of empagliflozin should greatly help implementation of these important findings into clinical practice for people living with chronic kidney disease,” added Co-Principal Investigator Professor Richard Haynes.

Key Points: 
  • “The approval of empagliflozin should greatly help implementation of these important findings into clinical practice for people living with chronic kidney disease,” added Co-Principal Investigator Professor Richard Haynes.
  • Empagliflozin demonstrated a significant kidney and cardiovascular benefit in adults with CKD, reducing the relative risk of kidney disease progression or cardiovascular death by 28 percent versus placebo.2,3
    “Across the EU, more than 47 million people are living with chronic kidney disease and even more with cardio-renal-metabolic conditions,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim.
  • “We are very excited about the potential for empagliflozin to play a key role in the management of these interconnected cardio-renal-metabolic conditions.”
    “Cardio-renal-metabolic conditions, like chronic kidney disease, type 2 diabetes and heart failure, are a leading cause of death in Europe.
  • We will continue working closely with regulators worldwide so that adults living with chronic kidney disease, and their health care providers, can benefit from empagliflozin as quickly as possible,” continued Leonard Glass, M.D., F.A.C.E., senior vice president, Diabetes & Obesity Global Medical Affairs, Lilly.

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older

Retrieved on: 
Wednesday, June 21, 2023
Hypersensitivity, Exercise, Insulin, Diet, Prevalence, Medicine, Type 2 diabetes, Diabetes, Diabetic ketoacidosis, Angioedema, Dialysis, Tablet, Boehringer Ingelheim, A1C, Excipient, LLY, Hypoglycemia, Lilly, Patient, Metformin, Risk, Eli Lilly and Company, Ageing, Regulatory affairs, FDA, Safety, III, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Medical device, F.A.C.E

RIDGEFIELD, Conn. and INDIANAPOLIS, June 21, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

Key Points: 
  • Jardiance is not recommended in patients with type 1 diabetes.
  • Jardiance is not recommended for use to improve glycemic control in patients with type 2 diabetes with an eGFR less than 30 mL/min/1.73 m2.
  • Type 2 diabetes represents a significant and growing health concern among young people in the U.S. Over the past two decades, the prevalence of type 2 diabetes in people aged 10-19 has nearly doubled.
  • New treatment options are critical to help address the over 5,700 new cases of type 2 diabetes in this population each year in the U.S.

DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

Retrieved on: 
Wednesday, June 21, 2023
Class Action Lawsuit, Professional Services, Legal, Eli Lilly and Company, DICE, LLY, Therapy, KSF, NYSE, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY).
  • Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions

Retrieved on: 
Tuesday, June 20, 2023
Abstract, Obesity, Diabetes, Doctor of Philosophy, Type 2 diabetes, LLY, Lilly, Comorbidity, American Diabetes Association, Overweight, Conditional sentence, Eli Lilly and Company, NAFLD, ADA, T2D, NYSE, Safety, Pharmaceutical industry, MD

INDIANAPOLIS, June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and obesity portfolio and pipeline at the American Diabetes Association's® (ADA) 83rd Scientific Sessions in San Diego from June 23 - 26. Lilly will also share data on three investigational medicines for the treatment of obesity or overweight during two ADA-sponsored symposiums and one oral presentation.

Key Points: 
  • INDIANAPOLIS, June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present 40 abstracts across its diabetes and obesity portfolio and pipeline at the American Diabetes Association's® (ADA) 83rd Scientific Sessions in San Diego from June 23 - 26.
  • Lilly will also share data on three investigational medicines for the treatment of obesity or overweight during two ADA-sponsored symposiums and one oral presentation.
  • "Our data presented at the ADA demonstrate continued efforts to deliver better outcomes for the millions of people living with diabetes, obesity and other chronic diseases," said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly.
  • "Our incretin portfolio, the most expansive in the industry, has the potential to transform treatment for chronic diseases."